Long-Term Use of Medication Does Not Improve Symptoms for Heart Failure Patients: Study

by Rukmani Krishna on March 1, 2013 at 7:36 PM
 Long-Term Use of Medication Does Not Improve Symptoms for Heart Failure Patients: Study

According to a study, among patients with heart failure with preserved ejection fraction, long-term treatment with the medication spironolactone improved left ventricular diastolic function but did not affect maximal exercise capacity, patient symptoms, or quality of life. The study is appearing in the February 27 issue of JAMA.

"Heart failure (HF) with preserved ejection fraction [EF; the percentage of blood that is pumped out of a filled ventricle as a result of a heartbeat is 50 percent or greater] accounts for more than 50 percent of the total HF population," according to background information in the article. There is not an established therapy for this condition, and aldosterone (a hormone) stimulation may contribute to its progression.


Frank Edelmann, M.D., of the University of Gottingen, Germany, and colleagues conducted a study to examine the long-term effects of spironolactone, an aldosterone receptor blocker, on diastolic function and exercise capacity in patients with HF with preserved EF. The Aldo-DHF trial, a randomized, placebo-controlled trial, was conducted between March 2007 and April 2012 at 10 sites in Germany and Austria. The study included 422 patients (average age, 67 years) with chronic New York Heart Association class II or III heart failure, preserved left ventricular ejection fraction of 50 percent or greater, and evidence of diastolic dysfunction. Patients were randomly assigned to receive 25 mg of spironolactone once daily (n = 213) or matching placebo (n = 209) with 12 months of follow-up. The primary outcomes measured were changes in diastolic function (E/e'') on echocardiography and maximal exercise capacity (peak VO2) on cardiopulmonary exercise testing.

The researchers found that spironolactone improved some measures (left ventricular end-diastolic filling, left ventricular remodeling, and neurohumoral activation). Maximal exercise capacity did not significantly change with spironolactone vs. placebo, and spironolactone did not improve heart failure symptoms or quality of life and slightly reduced 6-minute walking distance. "Spironolactone also modestly increased serum potassium levels and decreased estimated glomerular filtration rate without affecting hospitalizations."

The authors conclude that the "lack of accepted minimal clinically important differences in E/e'' or peak VO2 in HF with preserved EF warrants additional prospective, randomized, adequately powered studies to further evaluate the effect of improving diastolic function on symptomatic, functional, and clinical end points."
(JAMA. 2013;309(8):781-791; Available pre-embargo to the media at

Editor''s Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

Editorial: Defining Diastolic Heart Failure and Identifying Effective Therapies

"Ultimately, Aldo-DHF trial provides valuable new information but is not particularly reassuring in terms of either the efficacy or safety of mineralocorticoid antagonists (MRAs) for patients with heart failure with preserved ejection fraction (HFpEF),"writes John G. F. Cleland, M.D., Ph.D., F.R.C.P., and Pierpaolo Pellicori, M.D., of the University of Hull, Kingston-upon-Hull, England, in an accompanying editorial.

"In the meantime, MRAs appear useful for managing congestion and preventing diuretic-induced hypokalemia [abnormally low level of potassium in the circulating blood] with the attendant risk of sudden arrhythmic death. It is likely that these benefits are independent of cardiac phenotype but might be more prominent in those with impaired aldosterone degradation due to hepatic congestion. Whether MRAs exert important benefits for patients with HFpEF through other mechanisms such as reducing fibrosis, inflammation, and adrenergic activity may take longer to unravel."

Source: Newswise
Font : A-A+



Recommended Readings

Latest Heart Disease News

Heart Attack Fatalities Mark 12.5% Increase in 2022
The number of heart attack fatalities showed a notable increase, declining from 28,579 in 2020 to 28,413 in 2021, then surging to 32,457 in 2022.
Smart Watch Helps Detect Irregular Heart Rhythm
Atrial fibrillation (irregular heart rhythm) can be accurately diagnosed with Verily Study Watch, the FDA-approved wrist-worn gadget.
Red Flags in Red Cells — Decoding Their Threat on Heart Health!
According to health experts, an increased risk of heart attack, stroke, and blood clots is associated with higher hemoglobin levels.
Atherosclerosis in Young Adults Curbed by Early Risk Factor Management
Early cardiac evaluation reverses atherosclerosis caused by cardiac risk factors like high BP and high cholesterol in young adults.
Summer Wildfires and Winter Air Pollution Pose Varied Heart Health Risks
PM2.5 increases during winter inversions are associated with higher heart attack risk, stated study.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close

Long-Term Use of Medication Does Not Improve Symptoms for Heart Failure Patients: Study Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests